Recent Federal and State Reproductive Health Developments

Lexology July 9, 2024
Greenberg Traurig LLP

This GT Alert discusses various recent developments from the U.S. Supreme Court and Texas related to reproductive health.

Supreme Court Dismisses Challenge to FDA Approval of Mifepristone

On June 13, 2024, the U.S. Supreme Court dismissed a challenge from a group of physicians identifying as the Alliance for Hippocratic Medicine to the Food and Drug Administration’s approval of mifepristone, a medication used to terminate pregnancies. The Court’s unanimous decision held that the physicians lacked standing to bring the challenge because they neither prescribed mifepristone nor used it themselves. Because the Court dismissed the challenge on standing grounds, the Court’s opinions did not reach the substantive issues the petitioners raised regarding the FDA’s regulation of mifepristone, including whether FDA actions in...

Today's Sponsors

Today's Sponsor